Table 2 Baseline immune metabolic characteristics between responders and non-responders

Total HP ¹³C signal (tC) (10¹²)

2.3 ± 0.3

2.4 ± 0.1

.725

HP [1-¹³C]-pyruvate-to-tC ratio (%)

91.5 ± 3.5

74.4 ± 1.6

.011

HP [1-¹³C]-lactate-to-tC ratio (%)

3.6 ± 2.5

19.9 ± 2.4

.009

HP [1-¹³C]-alanine-to-tC ratio (%)

0.7 ± 0.2

0.9 ± 0.6

.767

HP [¹³C]-bicarbonate-to-tC ratio (%)

0.6 ± 0.4

0.2 ± 0.0

.334

Spleen volume (10² cm³)

1.1 ± 0.0

1.5 ± 0.3

.161

Spleen ADC (10⁻³ mm²/s)

1.2 ± 0.0

1.6 ± 0.3

.199

WBC count (10³/mL)

7.6 ± 0.4

12.1 ± 5.2

.443

Segmented neutrophil (%)

69.4 ± 0.9

70.4 ± 9.4

.918

Lymphocyte (%)

24.3 ± 1.1

19.3 ± 7.5

.545

Blood pyruvate (dmol/L)

0.2 ± 0.0

0.2 ± 0.0

.897

Blood lactate (dmol/L)

3.1 ± 0.6

2.8 ± 0.8

.812

Blood alanine (dmol/L)

0.7 ± 0.1

0.6 ± 0.2

.956

Urine pyruvate/creatinine (%)

0.7 ± 0.1

0.7 ± 0.1

.954

Urine lactate/creatinine (%)

2 ± 0.4

3.2 ± 0.4

.101

Urine alanine/creatinine (%)

3.4 ± 0.8

4 ± 0.9

.677

Tumor size (cm)

3.9 ± 0.6

5.3 ± 0.8

.240

Tumor ADC (10⁻³ mm²/s)

0.8 ± 0.0

0.8 ± 0.0

.599